A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer

I'm Daniel Levine, and this is the Bio Report. Non muscle invasive bladder cancer is a common slow progressing form of bladder cancer that makes up a majority of the roughly half a million new cases diagnosed each year. For decades, doctors have relied on a weakened bacterium called BCG in intravesical immunotherapy as a standard treatment for early stage disease, but it fails in about thirty to forty percent of patients. Engene is taking a different approach with Detalimigene, an experimental nonviral gene therapy designed to trigger a powerful but localized immune response right where the cancer lives in the bladder. We spoke with Ron Cooper, CEO of Engene, about this therapy for non muscle invasive bladder cancer, how its dual payload is meant to activate both an innate and adaptive immune response in the bladder, and the company's $130,000,000 financing at the 2025. Ron, thanks for joining us. Well, thank you. It's a real pleasure to be here. We're gonna talk about non muscle invasive bladder cancer, Ngene, and its efforts to develop the first non viral gene therapy for bladder cancer. Let's start with non muscle invasive bladder cancer. What is it? So, Danny, add non muscle invasive bladder cancer, otherwise called NMIBC, you know, is a form of bladder cancer that when you think about it's confined to the inner lining of the bladder and hasn't grown into the bladder muscle as yet. It's a pretty common cancer. It's the six most common by incidence. And, you know, when you look at bladder cancer overall, the totality of bladder cancer, non muscle invasive bladder cancer, NMI BC is the vast majority about seventy five to eighty, eighty five percent of it. And when you think about, you know, cancers and different types of cancers, the way to think about NMI BC, this is sort of a slow progressing type of cancer. So these, you know, these patients go through a multiyear journey. And how does it typically manifest itself and progress? So the early signs are usually, usually blood that's found in the urine or urinary symptoms that are confused with the UTI. So so discomfort. You know, most, most NMIVC patients are predominantly male. They're probably in their mid mid seventies or often individuals, you know, that are that are smokers. And then what happens is, you know, a urologist will investigate, you know, if they see any suspicious tissue, they'll surgically remove that. But as I said, you know, this is a multiyear journey. So the disease itself progresses fully. About twenty percent, you know, over ten years is the progression towards the muscle invasive version of, bladder cancer. And what's the prognosis for someone diagnosed with the condition day, and what treatment options exist? So NMIVC is a slow disease, but it's a serious disease, right? Particularly if the disease progresses to muscle invasive or metastatic, disease. And so it's so because it's a slow disease, it's a pretty high burden on the …